Abstract：
A high level of anti-BP180 antibodies on enzyme-linked immunosorbent assay and a persistent positive direct immunofluorescence at the end of treatment (immunologic tests, [ITs]) are predictors of relapse after treatment cessation (TC) in patients with bullous pemphigoid.
To evaluate the real-life impact of the immunologic-based decision of TC on the 3- and 6-month relapse rates after TC in bullous pemphigoid.
Retrospective multicentric study included patients followed almost 6 months after TC. Patients were classified according to whether the TC decision was in accordance with the results of ITs performed during the 3 months before TC, despite the results of ITs or without ITs performed.
We included 238 patients. Three months after TC, 36 patients showed relapse: 14 of 95 patients with TC in accordance with IT results (14.7%); 5 of 21 with TC despite ITs (23.8%); and 17 of 122 with TC without ITs (13.9%; P = .5). Six months after TC, the relapse rate was 18.9%, 28.6%, and 18.9% (P = .56), respectively, in the 3 groups.
The retrospective design and the limited follow up.
In real-life practice, in bullous pemphigoid, the 3- and 6-month relapse rates were not significantly reduced with TC decision based on results of ITs as compared with a classic clinical-based decision.
To evaluate the real-life impact of the immunologic-based decision of TC on the 3- and 6-month relapse rates after TC in bullous pemphigoid.
Retrospective multicentric study included patients followed almost 6 months after TC. Patients were classified according to whether the TC decision was in accordance with the results of ITs performed during the 3 months before TC, despite the results of ITs or without ITs performed.
We included 238 patients. Three months after TC, 36 patients showed relapse: 14 of 95 patients with TC in accordance with IT results (14.7%); 5 of 21 with TC despite ITs (23.8%); and 17 of 122 with TC without ITs (13.9%; P = .5). Six months after TC, the relapse rate was 18.9%, 28.6%, and 18.9% (P = .56), respectively, in the 3 groups.
The retrospective design and the limited follow up.
In real-life practice, in bullous pemphigoid, the 3- and 6-month relapse rates were not significantly reduced with TC decision based on results of ITs as compared with a classic clinical-based decision.
摘要：
在酶联免疫吸附测定中高水平的抗BP180抗体和治疗结束时持续阳性的直接免疫荧光（免疫学测试，[ITs]）是大疱性类天疱疮患者停止治疗（TC）后复发的预测因子。
评估基于免疫学的TC决定对大疱性类天疱疮TC后3个月和6个月复发率的现实生活影响。
回顾性多中心研究包括患者在TC后随访近6个月。根据TC决定是否与TC前3个月进行的ITs结果进行分类，尽管有ITs的结果或没有执行ITs。
我们纳入了238名患者。TC后三个月，36例患者出现复发：符合IT结果的95例TC患者中有14例（14.7％）；尽管有IT，但仍有TC的21例中有5例（23.8％）；122例TC无IT的17例（13.9％；P=5）。TC后六个月，复发率为18.9%，28.6%,和18.9%（P=0.56），分别,在3组。
回顾性设计和有限的随访。
在现实生活中,在大疱性类天疱疮中，与经典的基于临床的决定相比,基于ITs结果的TC决定的3个月和6个月复发率没有显著降低.
评估基于免疫学的TC决定对大疱性类天疱疮TC后3个月和6个月复发率的现实生活影响。
回顾性多中心研究包括患者在TC后随访近6个月。根据TC决定是否与TC前3个月进行的ITs结果进行分类，尽管有ITs的结果或没有执行ITs。
我们纳入了238名患者。TC后三个月，36例患者出现复发：符合IT结果的95例TC患者中有14例（14.7％）；尽管有IT，但仍有TC的21例中有5例（23.8％）；122例TC无IT的17例（13.9％；P=5）。TC后六个月，复发率为18.9%，28.6%,和18.9%（P=0.56），分别,在3组。
回顾性设计和有限的随访。
在现实生活中,在大疱性类天疱疮中，与经典的基于临床的决定相比,基于ITs结果的TC决定的3个月和6个月复发率没有显著降低.
